Hunter Syndrome Treatment Market Share,Size and Forecast 2019-2026

SKU: DHC269 | Last Updated On: 2019-08-16 | No. of Pages: 181 | Available Formats

( 39 Samples have been requested. )
In February 2019, the European Medicines Agency (EMA) granted orphan designation of JR-141 for Hunter Syndrome manufactured by JCR Pharmaceuticals Co., Ltd.

Hunter Syndrome Treatment Market

The global hunter syndrome treatment market was worth $XX million in 2018 and is forecasted to reach $XX million by 2026, at a CAGR of XX% during the forecast period.

Hunter syndrome is also known as mucopolysaccharidosis type II, and it affects several parts of the body. It is an inherited genetic disorder (an X-linked recessive disorder) caused by the missing or malfunctioning iduronate-2-sulfatase enzyme and can be severe or mild. Patients are suffering from a severe form of the disease experience a rapid decline in intellectual function as it progresses. Patients start losing basic functional skills between the ages of 6 and 8. The normal life expectancy of these people reduces to 10 to 20 years. Mild type condition also reduces the life span, but the individuals live into adulthood without getting their intelligence effected. Major causes of death in individuals with Hunter syndrome is airway obstruction and heart diseases. Diagnostic tests such as iduronate-2-sulfatase (I2S) enzyme activity test, genetic testing, and urine test are performed to diagnose the disease.

Hunter syndrome has no permanent cure; hence, the treatment mainly focuses on management of indications and difficulties associated with disease progression. Hunter syndrome’s treatment regime is designed based on the severity of symptoms and varies from patient-to-patient. According to the National Institute of Health (NIH) in 2018, Hunter syndrome affected around one per 160,000 males.

Global Hunter Syndrome Treatment Market Dynamics

The market is driven by a rising patient population of Hunter syndrome, potential approval of pipeline drugs globally, increasing healthcare expenses, fee reductions and grants, and favorable regulations.

Success for the drugs in pipeline with faster market  access and favorable regulations for their approval are needed to cope up with the fast-growing prevalence of the disease. To increase patient benefits, novel therapeutics such as gene therapy and RNA therapeutics are gaining popularity. In 2018, the National Institute of Neurological Disorders and Stroke (NINDS) funded research for the termination of the material buildup in brain cells through a virus delivered gene therapy showed improvement in memory and learning.

The high cost of therapy and lack of awareness can hamper the growth of the market in the forecast period.

Global Hunter Syndrome Treatment Market Segmentation

The global Hunter syndrome treatment market can be segmented by treatment type as Enzyme Replacement Therapy (ERT), Hematopoietic Stem Cell Transplant (HSCT) and others and by end-users – hospitals, clinics, specialty care unit and others.

Based on treatment type, ERTs are expected to dominate the market in the period of forecast. ERT uses an IV to replace a deficient or missing enzyme in the body. ERT does not cure the disease but slows its progression by increasing the amount of missing enzyme in the body. Elaprase (idursulfase) is a long-term ERT for patients with a confirmed diagnosis of MPS II and has been approved for use in the US, Canada, and many countries in Europe. Elaprase is developed and manufactured by Shire Pharmaceuticals and is given as weekly infusions. Strong sales of Elaprase and potential worldwide approval for the treatment of Hunter syndrome are some of the factors responsible for the rapid growth of ERT. Shire’s Elaprase (idursulfase) is the single primary drug for the treatment of mucopolysaccharidosis type worldwide, with GC Pharma’s Hunterase (idursulfase beta) being approved only in South Korea currently. According to NIH, around 2,000 patients globally are candidates for enzyme replacement therapy.

Global Hunter Syndrome Treatment Market Geographical Analysis

Geographically, the global hunter syndrome treatment market is divided into North America, Europe, South America, Asia-Pacific, and the Middle East and Africa.

North America is expected to account for the predominant  market share in the period of forecast due to favorable government regulations for orphan drug development, improving awareness on diagnosis and tretament of rare diseases, increased funding for research activities and improved healthcare facilities. The US government provides health insurance coverage and reimbursement of expensive drugs such as Elaprase for the treatment of Hunter syndrome

Asia Pacific region is expected to exhibit highest CAGR over the period of forecast due to the large target population in emerging countries such as India and China, improvement in healthcare infrastructure and significant opportunities for biopharmaceutical companies to penetrate the region.

Global Hunter Syndrome Treatment Market Competitive Analysis

Some of the major key players in the market are Takeda Pharmaceutical Company Limited, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., ArmaGen Inc., Inventiva S.A., Denali Therapeutics Inc., Bioasis Technologies Inc., BioMarin Pharmaceutical, Inc., and Esteve.

Key players in the market are engaged in the development of novel technologies, strategic planning, and alliances to achieve extensive growth, acquire a leading position in the market, and increase geographical footprints.

In January 2019, Takeda Pharmaceutical Company Limited acquired Shire plc expanding its geographic footprint and leading position in Japan and the U.S.

In November 2018, REGENXBIO Inc. announced that the first subject in Phase I/II study of RGX-121 has been successful for the treatment of Mucopolysaccharidosis Type II.

In June 2018, JCR Pharmaceuticals Co., Ltd. announced that Pharmaceutical and Medical Devices Agency (PMDA), completed the review of Phase 3 clinical trial plan for JR-141 in Japan.

In May 2018, FDA granted fast track designation for RGX-121 that is a novel, one-time investigational treatment for Mucopolysaccharidosis Type II, that is designed to deliver the human iduronate 2-sulfatase (I2S) gene directly to the CNS using the NAV AAV9 vector.

Why purchase the report?

  • Visualize the composition of the Hunter syndrome treatment market across each indication, in terms of type and by type highlighting the key commercial assets and players.
  • Identify commercial opportunities in Hunter syndrome treatment by analyzing trends and co-development deals.
  • Excel data sheets with thousands of data points of Hunter syndrome treatment market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players.

Target Audience:

  • Medical device companies
  • Hospitals and clinics
  • Research and consulting firms
  • Healthcare associations/institutes
  • Venture capitalists
  • Government agencies

Hunter Syndrome Treatment Market

  1. Global Hunter Syndrome Treatment Market Methodology and Scope

    1. Research Methodology
    2. Research Objective and Scope of the Report
  2. Global Hunter Syndrome Treatment Market – Market Definition and Overview

  3. Global Hunter Syndrome Treatment Market – Executive Summary

    1. Market Snippet by Treatment Type
    2. Market Snippet by End User
    3. Market Snippet by Region
    4. DataM CLO Scenario
  4. Global Hunter Syndrome Treatment Market Dynamics

    1. Market Impacting Factors
    2. Drivers
      1. Rising patient population of hunter syndrome
      2. Potential approval of pipeline drugs globally
      3. Increasing healthcare expenses and fee reductions
      4. Government grants and favorable regulations
    3. Restraints
      1. High cost of the drugs and treatment
      2. Lack of awareness
    4. Opportunity
    5. Impact Analysis
  5. Global Hunter Syndrome Treatment Market – Industry Analysis

    1. Porter's Five Forces Analysis
    2. Epidemiology
  6. Global Hunter Syndrome Treatment Market – By Treatment Type

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
    3. Market Attractiveness Index, By Treatment Type
    4. Enzyme Replacement Therapy (ERT)
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    5. Hematopoietic Stem Cell Transplant (HSCT)
    6. Others
  7. Global Hunter Syndrome Treatment Market – By End User

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
    3. Market Attractiveness Index, By End User
    4. Hospitals
      1. Introduction
      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026
    5.  Clinics
    6. Specialty Care Unit
    7.  Others
  8. Global Hunter Syndrome Treatment Market – By Region

    1. Introduction
    2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    3. Market Attractiveness Index, By Region
    4. North America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. U.S.
        2. Canada
        3. Mexico
    5. Europe
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Germany
        2. U.K.
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
    6. South America
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. Brazil
        2. Argentina
        3. Rest of South America
    7. Asia-Pacific
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
        1. China
        2. India
        3. Japan
        4. Australia
        5. Rest of Asia Pacific
    8. The Middle East and Africa
      1. Introduction
      2. Key Region-Specific Dynamics
      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
  9. Global Market – Competitive Landscape

    1. Competitive Scenario
    2. Competitor Hunter Syndrome Treatment Strategy Analysis
    3. Comparative Product Portfolio Analysis
    4. Market Positioning/Share Analysis
    5. Mergers and Acquisitions Analysis
  10. Company Profiles

    1. Takeda Pharmaceutical Company Limited *
      1. Company Overview
      2. Product Portfolio and Description
      3. Key Highlights
      4. Financial Overview
    2. GC Pharma
    3. JCR Pharmaceuticals Co. Ltd.
    4. RegenxBio Inc.
    5. Sangamo Therapeutics, Inc.
    6. ArmaGen Inc.
    7. Inventiva S.A.
    8. Denali Therapeutics Inc.
    9. Bioasis Technologies Inc.
    10. BioMarin Pharmaceutical, Inc.
    11. Esteve
  11. Global Hunter Syndrome Treatment Market – Premium Insights

  12. Global Hunter Syndrome Treatment Market – DataM

    1. Appendix
    2. About Us and Services
    3. Contact Us

List of Tables

Table 1 Global Hunter Syndrome Treatment Market Value, By Treatment Type, 2018,2022 & 2026 ($ Million)

Table 2 Global Hunter Syndrome Treatment Market Value, By End User, 2018,2022 & 2026 ($ Million)

Table 3 Global Hunter Syndrome Treatment Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 4 Global Hunter Syndrome Treatment Market Value, By Treatment Type, 2018,2022 & 2026 ($ Million)

Table 5 Global Hunter Syndrome Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 6 Global Hunter Syndrome Treatment Market Value, By End User, 2018,2022 & 2026 ($ Million)

Table 7 Global Hunter Syndrome Treatment Market Value, By End User, 2017-2026 ($ Million)

Table 8 Global Hunter Syndrome Treatment Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 9 Global Hunter Syndrome Treatment Market Value, By Region, 2017-2026 ($ Million)

Table 10 North America Hunter Syndrome Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 11 North America Hunter Syndrome Treatment Market Value, By End User, 2017-2026 ($ Million)

Table 12 North America Hunter Syndrome Treatment Market Value, By Country, 2017-2026 ($ Million)

Table 13 South America Hunter Syndrome Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 14 South America Hunter Syndrome Treatment Market Value, By End User, 2017-2026 ($ Million)

Table 15 South America Hunter Syndrome Treatment Market Value, By Country, 2017-2026 ($ Million)

Table 16 Europe Hunter Syndrome Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 17 Europe Hunter Syndrome Treatment Market Value, By End User, 2017-2026 ($ Million)

Table 18 Europe Hunter Syndrome Treatment Market Value, By Country, 2017-2026 ($ Million)

Table 19 Asia-Pacific Hunter Syndrome Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 20 Asia-Pacific Hunter Syndrome Treatment Market Value, By End User, 2017-2026 ($ Million)

Table 21 Asia-Pacific Hunter Syndrome Treatment Market Value, By Country, 2017-2026 ($ Million)

Table 22 Middle East & Africa Hunter Syndrome Treatment Market Value, By Treatment Type, 2017-2026 ($ Million)

Table 23 Middle East & Africa Hunter Syndrome Treatment Market Value, By End User, 2017-2026 ($ Million)

Table 24 Takeda Pharmaceutical Company Limited: Overview

Table 25 Takeda Pharmaceutical Company Limited: Product Portfolio

Table 26 Takeda Pharmaceutical Company Limited: Key Developments

Table 27 GC Pharma: Overview

Table 28 GC Pharma: Product Portfolio

Table 29 GC Pharma: Key Developments

Table 30 JCR Pharmaceuticals Co. Ltd.: Overview

Table 31 JCR Pharmaceuticals Co. Ltd.: Product Portfolio

Table 32 JCR Pharmaceuticals Co. Ltd.: Key Developments

Table 33 RegenxBio Inc.: Overview

Table 34 RegenxBio Inc.: Product Portfolio

Table 35 RegenxBio Inc.: Key Developments

Table 36 Sangamo Therapeutics, Inc.: Overview

Table 37 Sangamo Therapeutics, Inc.: Product Portfolio

Table 38 Sangamo Therapeutics, Inc.: Key Developments

Table 39 ArmaGen Inc.: Overview

Table 40 ArmaGen Inc.: Product Portfolio

Table 41 ArmaGen Inc.: Key Developments

Table 42 Inventiva S.A.: Overview

Table 43 Inventiva S.A.: Product Portfolio

Table 44 Inventiva S.A.: Key Developments

Table 45 Denali Therapeutics Inc.: Overview

Table 46 Denali Therapeutics Inc.: Product Portfolio

Table 47 Denali Therapeutics Inc.: Key Developments

Table 48 Bioasis Technologies Inc.: Overview

Table 49 Bioasis Technologies Inc.: Product Portfolio

Table 50 Bioasis Technologies Inc.: Key Developments

Table 51 BioMarin Pharmaceutical, Inc.: Overview

Table 52 BioMarin Pharmaceutical, Inc.: Product Portfolio

Table 53 BioMarin Pharmaceutical, Inc.: Key Developments

 

 

 

 

 

 

 

 

 

 

 List of Figures

Figure 1 Global Hunter Syndrome Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 2 Global Hunter Syndrome Treatment Market Share, By End User, 2018 & 2026 (%)

Figure 3 Global Hunter Syndrome Treatment Market Share, By Region, 2018 & 2026 (%)

Figure 4 Global Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 5 Global Hunter Syndrome Treatment Market Y-o-Y Growth, By Treatment Type, 2018-2026 (%)

Figure 6 Enzyme Replacement Therapy: Global Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 7 Hematopoietic Stem Cell Transplant : Global Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 8 Others: Global Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 9 Global Hunter Syndrome Treatment Market Y-o-Y Growth, By End User, 2018-2026 (%)

Figure 10 Hospitals: Global Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 11 Clinics: Global Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 12 Specialty Care Unit: Global Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 13 Others: Global Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 14 Global Hunter Syndrome Treatment Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 15 North America Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 16 North America Hunter Syndrome Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 17 North America Hunter Syndrome Treatment Market Share, By End User, 2018 & 2026 (%)

Figure 18 North America Hunter Syndrome Treatment Market Share, By Country, 2018 & 2026 (%)

Figure 19 South America Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 20 South America Hunter Syndrome Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 21 South America Hunter Syndrome Treatment Market Share, By End User, 2018 & 2026 (%)

Figure 22 South America Hunter Syndrome Treatment Market Share, By Country, 2018 & 2026 (%)

Figure 23 Europe Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 24 Europe Hunter Syndrome Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 25 Europe Hunter Syndrome Treatment Market Share, By End User, 2018 & 2026 (%)

Figure 26 Europe Hunter Syndrome Treatment Market Share, By Country, 2018 & 2026 (%)

Figure 27 Asia-Pacific Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 28 Asia-Pacific Hunter Syndrome Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 29 Asia-Pacific Hunter Syndrome Treatment Market Share, By End User, 2018 & 2026 (%)

Figure 30 Asia-Pacific Hunter Syndrome Treatment Market Share, By Country, 2018 & 2026 (%)

Figure 31 Middle East & Africa Hunter Syndrome Treatment Market Value, 2017-2026 ($ Million)

Figure 32 Middle East & Africa Hunter Syndrome Treatment Market Share, By Treatment Type, 2018 & 2026 (%)

Figure 33 Middle East & Africa Hunter Syndrome Treatment Market Share, By End User, 2018 & 2026 (%)

Figure 34 Takeda Pharmaceutical Company Limited: Financials

Figure 35 GC Pharma: Financials

Figure 36 JCR Pharmaceuticals Co. Ltd.: Financials

Figure 37 RegenxBio Inc.: Financials

Figure 38 Sangamo Therapeutics, Inc.: Financials

Figure 39 ArmaGen Inc.: Financials

Figure 40 Inventiva S.A.: Financials

Figure 41 Denali Therapeutics Inc.: Financials

Figure 42 Bioasis Technologies Inc.: Financials

Figure 43 BioMarin Pharmaceutical, Inc.: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report